Clinical Outcomes in Patients With COVID-19 and Hematologic Disease

Gavrilina, O A; Zakurdaeva, Kristina; Vasileva, Anastasia N.; Dubov, Sergey K.; Dubov, Vitaly S.; Vorobyev, Vladimir I.; Butaev, Lev S.; Sukhareva, Alena M.; Гаврилова, Л. В.; Toropova, Inessa Yu.; Popova, M.; Siniaev, A.; Kaplanov, Kamil; Петренко, А А; Ochirova, Oksana; Karpova, Alina; Chelysheva, Ekaterina; Turkina, Anna; Gurianova, Margarita; Al-Radi, Lyubov; Gilyazitdinova, E A; Егорова, Е К; Chabaeva, Yulia; Kulikov, Sergey; Sveshnikova, Yu. V.; Kunst, Mikhail A.; Shuvaev, Vasily; Rakhmani, Anzhelika F.; Panteleeva, Olga L.; Grishunina, Maria; Samoylova, Olga; Vorontsova, Ekaterina; Барышникова, Д. В.; Паровичникова, Е Н

doi:10.1016/j.clml.2023.04.002

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although patients with hematologic diseases and end-stage chronic kidney disease also showed a trend towards increased risk for severe outcomes, this did not reach significance, probably due to the smaller sample size for these less prevalent diseases. However, the trend is consistent with data provided from other observational studies [ 1 , 34 ].…”

Section: Discussionsupporting

confidence: 92%

Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study

Nachtigall,

Kwast,

Hohenstein

et al. 2024

Vaccines

View full text Add to dashboard Cite

Aims: Endemic SARS-CoV-2 infections still burden the healthcare system and represent a considerable threat to vulnerable patient cohorts, in particular immunocompromised (IC) patients. This study aimed to analyze the in-hospital outcome of IC patients with severe SARS-CoV-2 infection in Germany. Methods: This retrospective, observational study, analyzed administrative data from inpatient cases (n = 146,324) in 84 German Helios hospitals between 1 January 2022 and 31 December 2022 with regard to in-hospital outcome and health care burden in IC patients during the first 12 months of Omicron dominance. As the primary objective, in-hospital outcomes of patients with COVID-19-related severe acute respiratory infection (SARI) were analyzed by comparing patients with (n = 2037) and without IC diagnoses (n = 14,772). Secondary analyses were conducted on IC patients with (n = 2037) and without COVID-19-related SARI (n = 129,515). A severe in-hospital outcome as a composite endpoint was defined per the WHO definition if one of the following criteria were met: intensive care unit (ICU) treatment, mechanical ventilation (MV), or in-hospital death. Results: In total, 12% of COVID-related SARI cases were IC patients, accounting for 15% of ICU admissions, 15% of MV use, and 16% of deaths, resulting in a higher prevalence of severe in-hospital courses in IC patients developing COVID-19-related SARI compared to non-IC patients (Odds Ratio, OR = 1.4, p < 0.001), based on higher in-hospital mortality (OR = 1.4, p < 0.001), increased need for ICU treatment (OR = 1.3, p < 0.001) and mechanical ventilation (OR = 1.2, p < 0.001). Among IC patients, COVID-19-related SARI profoundly increased the risk for severe courses (OR = 4.0, p < 0.001). Conclusions: Our findings highlight the vulnerability of IC patients to severe COVID-19. The persistently high prevalence of severe outcomes in these patients in the Omicron era emphasizes the necessity for continuous in-hospital risk assessment and monitoring of IC patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study

Nachtigall,

Kwast,

Hohenstein

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Пациенты онкологического и гематологического профилей демонстрируют повышенные риски неблагоприятных исходов COVID-19, о чем свидетельствуют многочисленные международные и российские научные работы [34][35][36]. В публикации 2023 г. по данным многоцентрового наблюдательного проспективного когортного исследования российской популяции онкогематологических пациентов выявлен значительный показатель смертности (18,9%) в течение 30 дней от инфекции COVID-19, большая часть больных (81%) погибли от осложнений COVID-19.…”

Section: информация об авторах / Information About the Authorsunclassified

“…Летальность различалась в зависимости от основного диагноза пациентов: для острых лейкозов показатель составлял 29% (36% в группе острого миелоидного лейкоза, 19% -острого лимфобластного лейкоза, 10% -острого промиелоцитарного лейкоза), 33% -среди пациентов с диагнозом хронического лимфолейкоза, 26% -миелодиспластического синдрома, 23% -с хроническими миелопролиферативными заболеваниями. Изменение схемы терапии основного заболевания, задержка или отмена курса лечения имели место в 63% наблюдений [34]. Несмотря на появление вакцин против COVID-19 и преобладание вариантов штамма Омикрон, показатель смертности среди онкогематологических пациентов после проведения полного курса вакцинации (2 дозы и более) составлял 9%, что может быть связано с отсутствием адекватного гуморального ответа на активную иммунизацию [37].…”

Section: информация об авторах / Information About the Authorsunclassified

The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic

Avdeev,

Chulanov,

Alexeeva

et al. 2023

Terapevticheskii arkhiv

Self Cite

View full text Add to dashboard Cite

On July 3, 2023, an interdisciplinary Council of Experts The burden of COVID-19 in a heterogeneous population of immunocompromised patients post-pandemic realities was held in Moscow with leading experts in pulmonology, rheumatology, hematology, oncology, nephrology, allergology-immunology, transplantation, and infectious diseases. The aim of the meeting was to discuss the current clinical and epidemiologic situation related to COVID-19, the relevance of disease prevention strategies for high-risk patients. The experts addressed the following issues: 1) the disease burden of COVID-19 in 2023 for patients with immunodeficiency in different therapeutic areas; 2) the place of passive immunization with monoclonal antibodies as a method of COVID-19 prophylaxis among immunocompromised patients; 3) prerequisites for the inclusion of passive immunization of immunocompromised patients into routine clinical practice.

show abstract

Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis

Akbarzadeh,

Vaez-Gharamaleki,

Jahanshahlou

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Clinical Outcomes in Patients With COVID-19 and Hematologic Disease

Cited by 4 publications

References 26 publications

Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study

Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study

The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic

Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis

Contact Info

Product

Resources

About